{"analyses":[{"ciLowerLimit":"11.8","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"29.3","estimateComment":"The 95% stratified Newcombe CI with CMH weights","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","pValueComment":"If the primary endpoint is significant, a fixed sequence procedure was employed to control the overall type I error rate of the key secondary endpoints.","paramType":"Difference estimated using CMH weights","paramValue":"21.1","statisticalComment":"Stratified by Previous biologic agent and/or JAK inhibitors exposure, Use of oral corticosteroids treatment at Week 0, Clinical remission at Week 10.","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"30"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"294"},{"groupId":"OG001","value":"144"}],"units":"Participants"}],"description":"Clinical remission defined by modified Mayo score which ranges from 0 to 9, including Stool frequency subscore, Rectal bleeding subscore and Endoscopic subscore but excluding Physician's global assessment subscore from the Total Mayo score.\n\nPatients with dose adjustment to CT-P13 SC 240 mg prior to Week 54 were considered as non-remitter.","groups":[{"description":"CT-P13 SC 120 mg","id":"OG000","title":"CT-P13 SC 120 mg"},{"description":"Placebo","id":"OG001","title":"Placebo"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All-randomized population","reportingStatus":"POSTED","timeFrame":"Week 54","title":"Percentage of Patients Achieving Clinical Remission at Week 54","type":"PRIMARY","unitOfMeasure":"Participants"}